[HTML][HTML] The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification
JL Sauter, S Dacic, F Galateau-Salle… - Journal of Thoracic …, 2022 - Elsevier
Substantial changes in the 2021 WHO Classification of Tumors of the Pleura and
Pericardium since the 2015 WHO Classification include the following:(1) pleural and …
Pericardium since the 2015 WHO Classification include the following:(1) pleural and …
Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group
AN Husain, TV Colby, NG Ordóñez… - … of pathology & …, 2018 - meridian.allenpress.com
Context.—Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to
diagnose. Objective.—To provide updated, practical guidelines for the pathologic diagnosis …
diagnose. Objective.—To provide updated, practical guidelines for the pathologic diagnosis …
BAP1 links metabolic regulation of ferroptosis to tumour suppression
The roles and regulatory mechanisms of ferroptosis (a non-apoptotic form of cell death) in
cancer remain unclear. The tumour suppressor BRCA1-associated protein 1 (BAP1) …
cancer remain unclear. The tumour suppressor BRCA1-associated protein 1 (BAP1) …
Integrative molecular characterization of malignant pleural mesothelioma
J Hmeljak, F Sanchez-Vega, KA Hoadley, J Shih… - Cancer …, 2018 - aacrjournals.org
Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest
cavity. To expand our understanding of MPM, we conducted a comprehensive integrated …
cavity. To expand our understanding of MPM, we conducted a comprehensive integrated …
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Abstract Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in
FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions …
FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions …
New horizons for precision medicine in biliary tract cancers
JW Valle, A Lamarca, L Goyal, J Barriuso… - Cancer discovery, 2017 - aacrjournals.org
Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-
prognosis and low-incidence cancers, although the incidence of intrahepatic …
prognosis and low-incidence cancers, although the incidence of intrahepatic …
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Among more than 200 BAP1-mutant families affected by the “BAP1 cancer syndrome,”
nearly all individuals inheriting a BAP1 mutant allele developed one or more malignancies …
nearly all individuals inheriting a BAP1 mutant allele developed one or more malignancies …
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R Bueno, EW Stawiski, LD Goldstein, S Durinck… - Nature …, 2016 - nature.com
Abstract We analyzed transcriptomes (n= 211), whole exomes (n= 99) and targeted exomes
(n= 103) from 216 malignant pleural mesothelioma (MPM) tumors. Using RNA-seq data, we …
(n= 103) from 216 malignant pleural mesothelioma (MPM) tumors. Using RNA-seq data, we …
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent
approval of combination immune checkpoint blockade. Here we report the results of the …
approval of combination immune checkpoint blockade. Here we report the results of the …
Saturation genome editing of BAP1 functionally classifies somatic and germline variants
Many variants that we inherit from our parents or acquire de novo or somatically are rare,
limiting the precision with which we can associate them with disease. We performed …
limiting the precision with which we can associate them with disease. We performed …